*Please Note* The Study you are attempting to view was originally sponsored by Tanabe and acquired from Takeda by AstraZeneca and was disclosed initially by Takeda per their Transparency Policies. More information regarding this study may be available by contacting [email protected].
Chronic Obstructive Pulmonary Disease
Phase 1
Yes
-
Male
24
Interventional
20 Years - 45 Years
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Jun 2016 by Tanabe
Tanabe
-
No locations available
Arms | Assigned Interventions |
---|